CoChat
Sign Up
Cited by 218Medicinal Plant Extracts EffectsComplementary and Alternative Medicine StudiesAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

A Randomized, Double-Blind, Placebo-Controlled Trial of Oral Matricaria recutita (Chamomile) Extract Therapy for Generalized Anxiety Disorder

Open access
Amsterdam, Jay D., Li, Yimei, Soeller, Irene, Rockwell, Kenneth, Mao, Jun James, Shults, Justine·2009·Journal of Clinical Psychopharmacology
DOI 10.1097/jcp.0b013e3181ac935cPMC PMC3600416
Open this paper in CoChat — free account

Abstract

OBJECTIVE: We conducted a randomized, double-blind, placebo-controlled efficacy and tolerability trial of Matricaria recutita (chamomile) extract therapy in patients with mild to moderate generalized anxiety disorder (GAD). We hypothesized that chamomile would be superior to placebo in reducing GAD symptoms with a comparable tolerability profile. MATERIALS AND METHODS: Sixty-one outpatients with mild to moderate GAD were enrolled, and 57 were randomized to either double-blind chamomile extract (n = 28) or placebo therapy (n = 29) for 8 weeks. The study was powered to detect a statistically significant and clinically meaningful group difference in change over time in total Hamilton Anxiety Rating (HAM-A) scores. Secondary outcomes included change in the Beck Anxiety Inventory, Psychological Well Being, and Clinical Global Impression Severity scores and the proportion of patients with 50% reduction or more in baseline HAM-A score. RESULTS: We observed a significantly greater reduction in mean total HAM-A score during chamomile versus placebo therapy (P = 0.047). Although the study was not powered to identify small to moderate differences in secondary outcomes, we observed a positive change in all secondary outcomes in the same direction as the primary outcome measure. One patient in each treatment group discontinued therapy for adverse events. The proportion of patients experiencing 0, 1, 2, or 3 adverse events or more was not significantly different between groups (P = 0.417). CONCLUSIONS: This is the first controlled clinical trial of chamomile extract for GAD. The results suggest that chamomile may have modest anxiolytic activity in patients with mild to moderate GAD. Future studies are needed to replicate these observations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e3181ac935c

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 26 references

1 of the 26 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. 1985, Treatment Emergent Symptoms Scale (TESS)., Psychopharmacol Bull, 21, 1069

Cited by

Sorted by citations

Items 101–200 of 217

Related

See all

Metadata

Authors
Amsterdam, J. D., Li, Y., Soeller, I., Rockwell, K., Mao, J. J., & Shults, J.
Affiliations
University of Pennsylvania (US)
Corresponding author
  • Amsterdam, Jay D.
  • Soeller, Irene
ORCID
Venue
Journal of Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2009-08
Volume
29
Issue
4
Pages
378-382
ISSN
0271-0749 (ISSN-L)
DOI
10.1097/jcp.0b013e3181ac935c
PMC
PMC3600416
OpenAlex
W2091881469
Cited by
218
References
26
Citations by year
2026: 11 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 17 · 2021: 17 · 2020: 9 · 2019: 18 · 2018: 10 · 2017: 15 · 2016: 15 · 2015: 12 · 2014: 10 · 2013: 14 · 2012: 8
FWCI
20.38
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Mental Health (R01MH063818, R34MH070753, R01MH060713, R01MH060998, R01MH060353)
  • National Cancer Institute (R01CA096885)
  • National Center for Complementary and Integrative Health (R21AT001916, R21AT002289, AT001916)
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
chamomile, chamomile extract, generalized anxiety disorder, anxiolytic effects, herbal medicine, tolerability, Hamilton Anxiety Rating Scale, Beck Anxiety Inventory, psychological well-being
MeSH terms
Administration, Oral, Adult, Aged, Anxiety Disorders, Capsules, Double-Blind Method, Female, Humans, Male, Middle Aged, Plant Extracts, Psychiatric Status Rating Scales, Severity of Illness Index, Time Factors, Anti-Anxiety Agents, Treatment Outcome, Chamomile

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review